CellProtect Nordic Pharmaceuticals AB was founded in 2012 based on cell therapy research from the Karolinska Institutet and Karolinska University Hospital. The company is developing new therapies based on Natural Killer (NK) cells and mesenchymal stem cells (MSC). CPNP has 17 working shareholders with extensive experience from the life science industry support the company in several different fields.

​

CellProtect is currently the lead investigational drug candidate, and consists of autologous ex vivo expanded and activated NK cells, and is being evaluated as adjunct therapy in patients with multiple myeloma. A phase I/II study is being conducted at the Karolinska University Hospital. The company has acquired assets and legal rights related to CellProtect technology. CellProtect Nordic Pharmaceuticals has acquired SME status from EMA.

​

Role in project:

​

CPNP will perform the following roles:

1. Develop biomarker analyses on clinical samples and cell therapy products;

2. Conduct in-process control analyses;

3. Develop improved potency assays for clinical efficacy;

4. Provide regulatory advice for further clinical development;

5. Investigate future opportunities on commercialisation.

 

Contributing staff:

• Dr Karin Mellstrom

• Dr Lena Degling Wikingsson

• Mrs Vera Franzén